Global Communicable Diseases Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Type;

Sexually Transmitted Diseases, Helminthic Diseases, Contact Communicable Diseases, Oral Contamination Diseases, and Air Borne Diseases.

By Indication;

Gastroenteritis, Gonorrhea, Whooping Cough, Common Cold, Hiv/Aids, Pink Eye, Hepatitis, and Others.

By Treatment Type;

Vaccine, Therapeutics, and Others.

By Route of Administration;

Oral, Parenteral, and Others.

By Distribution Channel;

Hospitals, Retail Pharmacies, Specialty Clinics, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn155447625 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Communicable Diseases Treatment Market (USD Million), 2021 - 2031

In the year 2024, the Global Communicable Diseases Treatment Market was valued at USD 33,941.02 million. The size of this market is expected to increase to USD 52,999.56 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.6%.

Infectious diseases stem from various organisms, including bacteria, viruses, fungi, and parasites, with some being contagious and transferable between individuals. Transmission can occur through direct contact, via insect or animal bites, or ingestion of contaminated food or water. Common examples include Acquired Immunodeficiency Syndrome (AIDS), hepatitis B, and tuberculosis (TB). The global prevalence of these diseases, notably TB and AIDS, underscores the significant burden they impose on public health systems.

For instance, according to the Centers for Disease Control and Prevention, TB affected approximately one-third of the world's population in 2016, with 10.4 million people diagnosed, resulting in 1.7 million deaths globally. Similarly, the World Health Organization reported 36.7 million people living with HIV/AIDS in 2016, causing 1.0 million deaths worldwide.

Factors driving market growth include the increasing prevalence of infectious diseases, augmented research and development funding, and heightened awareness among patients. These factors contribute to the expansion of the infectious disease treatments market, as evidenced by the rising demand for pharmaceuticals targeting these diseases.

The challenges persist, including low adoption rates of treatments and relatively low per capita healthcare expenditure in developing economies, which may hinder market growth during the forecast period.

Despite these challenges, advancements in genomics and proteomics are expected to further propel market expansion. Additionally, factors such as growing government-funded programs, a shift towards decentralized point-of-care testing, and an increasing demand for personalized treatments are anticipated to bolster the infectious disease testing products market.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Indication
    3. Market Snapshot, By Treatment Type
    4. Market Snapshot, By Route of Administration
    5. Market Snapshot, By Distribution Channel
    6. Market Snapshot, By Region
  4. Global Communicable Diseases Treatment Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Prevalence of Communicable Diseases
        2. Advancements in Medical Technology and Treatment Options
        3. Government Initiatives and Funding
        4. Increasing Healthcare Expenditure
        5. Globalization and Travel
      2. Restraints
        1. Limited Access to Healthcare
        2. Antimicrobial Resistance (AMR)
        3. Vaccine Hesitancy and Misinformation
        4. Inadequate Public Health Infrastructure
        5. Socioeconomic Factors
      3. Opportunities
        1. Technological Advancements
        2. Rising Prevalence of Communicable Diseases
        3. Increased Research and Development
        4. Global Health Initiatives
        5. Healthcare Infrastructure Development
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation

    1. Global Communicable Diseases Treatment Market, By Type, 2021 - 2031 (USD Million)

      1. Sexually Transmitted Diseases
      2. Helminthic Diseases
      3. Contact Communicable Diseases
      4. Oral Contamination Diseases
      5. Air Borne Diseases
    2. Global Communicable Diseases Treatment Market, By Indication, 2021 - 2031 (USD Million)
      1. Gastroenteritis
      2. Gonorrhea
      3. Whooping Cough
      4. Common Cold
      5. Hiv/Aids
      6. Pink Eye
      7. Hepatitis
      8. Others
    3. Global Communicable Diseases Treatment Market, By Treatment Type, 2021 - 2031 (USD Million)
      1. Vaccine
      2. Therapeutics
      3. Others
    4. Global Communicable Diseases Treatment Market, By Route of Administration, 2021 - 2031 (USD Million)
      1. Oral
      2. Parenteral
      3. Others
    5. Global Communicable Diseases Treatment Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Retail Pharmacies
      3. Specialty Clinics
      4. Others
    6. Global Communicable Diseases Treatment Market, By Geography, 2021 - 2031 (USD Million)
      1. North America

        1. United States

        2. Canada

      2. Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Nordic

        7. Benelux

        8. Rest of Europe

      3. Asia Pacific

        1. Japan

        2. China

        3. India

        4. Australia & New Zealand

        5. South Korea

        6. ASEAN (Association of South East Asian Countries)

        7. Rest of Asia Pacific

      4. Middle East & Africa

        1. GCC

        2. Israel

        3. South Africa

        4. Rest of Middle East & Africa

      5. Latin America

        1. Brazil

        2. Mexico

        3. Argentina

        4. Rest of Latin America

  6. Competitive Landscape
    1. Company Profiles
      1. Bristol-Myers Squibb Pharmaceutical Ltd
      2. GlaxoSmithKline Plc
      3. Medtronic Inc
      4. Novartis International AG
      5. Pfizer Inc
      6. Sanofi SA
      7. Boehringer Ingelheim GmbH
      8. Eli Lilly and Company
      9. Johnson & Johnson Inc
      10. Merck & Co., Inc
      11. Novo Nordisk A/S
      12. F. Hoffmann-La Roche AG.
  7. Analyst Views
  8. Future Outlook of the Market